Bionomics Investor Presentation Deck
April 2022, 38 slides
  1. Bionomics
  2. Related Decks
  3. Investor Presentation Decks
to improve the lives of patients with serious disorders corporate presentation am a bionomics | Bionomics
safe harbor statement | Bionomics
emerging leader in neuropsychiatry | Bionomics
focused pipeline with multiple potential catalysts on the horizon | Bionomics
a differentiated approach the a nicotinic acetylcholine receptor | Bionomics
harnessing the power of a novel mechanism action of depends on acetylcholine and modulation of a a nach pad | Bionomics
in social anxiety disorder | Bionomics
targeting a large segment of the anxiety market an | Bionomics
significantly reduced panic symptoms in humans induced model total of panic symptoms panic symptom intensity placebo controlled study in healthy volunteers who experienced a induced panic attack demonstrated reduction in panic symptoms and intensity as measured with the panic symptom scale | Bionomics
demonstrated acute activity in gad phase performed | Bionomics
addresses the shortcomings of existing social anxiety disorder approaches mechanism | Bionomics
rapid onset of action is well positioned for social anxiety disorder prescribed off label have significant side effects of sedation cognitive impairment and potential for addiction growing unmet need based on improving awareness and evolving regulatory dynamics precedent on simplified public speaking challenge for acute anxiety reduction placebo be | Bionomics
phase prevail social anxiety disorder trial cost effective trial with an efficacy conducive to rapid data generation ability to leverage development plan and trial design for social anxiety disorder received clearance for filing and fast track designation phase trial underway and will read out topline data by end of fast track designation topline data fees | Bionomics
in post traumatic stress disorder | Bionomics
tackling the profound disease burden of post traumatic stress disorder | Bionomics
anti anxiety signals observed in animal models and human translational studies | Bionomics
is well positioned in post traumatic stress disorder | Bionomics
modeling target achieved with new dose solid formulation be | Bionomics
phase attune study underway phase fast track designation from topline data expected be week placebo key inclusion criteria | Bionomics
focused collaborations | Bionomics
ongoing strategic collaboration with a i partnership | Bionomics
mou for and derivative for post traumatic stress disorder memorandum of understanding with derivative daily news | Bionomics
investment highlights stock and financial information | Bionomics
stock and financial snapshot listing on two global exchanges lean operations with modest burn well capitalized through a us of net cash leading significant investors | Bionomics
bionomics outlook renewed value driving trajectory a | Bionomics
appendix management team board of directors | Bionomics
powered by a seasoned and experienced management team slink | Bionomics
appendix prior clinical trial information | Bionomics
compelling rationale in a multifaceted disorder | Bionomics
summary of clinical trials excellent safety and tolerability profile in healthy subjects and patients | Bionomics
mechanistic validation of as evidenced by response observed reduction in response due to negative modulation of the receptors blood brain barrier penetration and nicotinic receptor target engagement in humans be | Bionomics
phase trial of in adults with post traumatic stress disorder study design center randomized double blind placebo controlled and placebo liquid suspension formulation taken twice daily i week treatment period participants us sites sites key selection criteria current diagnosis of as defined by caps clinician administered scale for key study objectives to assess the effects of on investigator rated symptoms of measured by caps to assess the safety and tolerability of in subjects with be restore | Bionomics
trial overall conclusions no overall effect on primary of caps total severity score at weeks patients had a greater improvement over placebo than us patients evidence of effect in high dose treatment group in total population trend for effect in high dose treatment group in the total population was well tolerated in patients with be | Bionomics
emerging pipeline for partnering | Bionomics
ion channel activators for cognitive dysfunction and negative symptoms promising therapeutic strategy for improving cognitive and social withdrawal symptoms potential in schizophrenia autism spectrum disorders and conditions with cognitive impairments compounds synthesized series patented | Bionomics
pan inhibitors potential non reduced side effect chronic pain therapies disease related genetics gain loss of function mutations in and associated with human pain syndromes where extreme pain or no pain is experienced pan inhibitors small molecules with functional selectivity for voltage gated sodium channels and potentially compounds synthesized series patented lead candidate identified observed to reverse pain in the paw model in mice back up | Bionomics
appendix building value through legacy oncology assets | Bionomics
legacy oncology asset monetization to drive value exclusive license agreement for the development of car therapeutics exclusive agreement license bionomics drug candidate carina for the development of | Bionomics
See More
Bionomics
Investor Presentation Decks
Biotechnology Decks
Healthcare Decks
Explore Topics
Anxiety
Clinical trial
Clinical development
Recent decks by Bionomics
Results
March 2023
Investor Presentation
October 2022
Investor Presentation
June 2022
IPO
December 2021
See all presentations by Bionomics (5 decks)
Related decks
MindMed
Investor Presentation
June 2023
MindMed
Investor Presentation
January 2025
23andMe
Investor Presentation
January 2024
Legend Biotech
Investor Presentation
April 2025
Avenue Therapeutics
IPO
October 2022
Erasca
Investor Presentation
January 2024
RayzeBio
IPO
September 2023
MindMed
Investor Presentation
April 2021
Recent decks by Bionomics
See all presentations (5 decks)
Results
March 2023
Investor Presentation
October 2022
Investor Presentation
June 2022
IPO
December 2021
MindMed
Investor Presentation
June 2023
MindMed
Investor Presentation
January 2025
23andMe
Investor Presentation
January 2024
Legend Biotech
Investor Presentation
April 2025
Avenue Therapeutics
IPO
October 2022
Erasca
Investor Presentation
January 2024
RayzeBio
IPO
September 2023
MindMed
Investor Presentation
April 2021
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io